Azura Ophthalmics
Developing an innovative portfolio of compounds to advance treatments for Meibomian gland dysfunction , the leading cause of Dry Eye Disease.
Launch date
Employees
Market cap
-
Enterprise valuation
$80—120m (Dealroom.co estimates Oct 2020.)
Tel Aviv-Yafo Tel Aviv District (HQ)
| Date | Investors | Amount | Round |
|---|---|---|---|
$16.0m | Series B | ||
$20.0m | Series C | ||
* | N/A | Grant | |
| Total Funding | $36.0m | ||